MedPath

Optimizing Antibiotic Use in Neonatal Intensive Care Units in China

Not Applicable
Recruiting
Conditions
Neonates
Interventions
Behavioral: Collaborative Antimicrobial Stewardship Program (ASP)
Registration Number
NCT05073549
Lead Sponsor
Children's Hospital of Fudan University
Brief Summary

This project aims to reduce antibiotic use in Chinese neonatal intensive care units (NICU) by 1) developing an adaptable framework of NICU-targeted antimicrobial stewardship programs (ASP); 2) implementing the NICU-targeted ASP in NICUs using a collaborative quality improvement method; and 3) evaluating the impact of ASP implementation on neonatal antibiotic use.

Detailed Description

Antibiotics overuse has been a critical problem in Chinese NICUs associated with the emerging antimicrobial resistance crisis. NICU-targeted ASP have rarely been implemented in Chinese NICUs. Collaborative quality improvement methods have been shown to facilitate clinical practice changes and improve outcomes.

In this two-year interventional pre-and post-study, a NICU-targeted ASP will be developed and implemented in Chinese NICUs using the collaborative quality improvement method. The investigators hypothesize that implementing the targeted ASP using a collaborative quality improvement method will reduce the overall antibiotic days of therapy by 20% over a two-year period, comparing the last year of intervention and the last year of baseline period before ASP implementation.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
10000
Inclusion Criteria
  • All infants born at ≀31+6 weeks' gestation and admitted to the participating NICUs between October 1st, 2019 and September 30th, 2023.
  • The period from October 1st, 2019 to September 30th, 2021 will be used as the baseline period before ASP intervention. Clinical data of eligible infants in this period will be retrospectively collected from a previously established database of preterm infants.
  • The ASP implementation will be initiated on October 1st, 2021. The period from October 1st, 2021 to September 31st, 2023 will be the ASP intervention period and data will be prospectively collected.
Exclusion Criteria
  • Infants who are transferred to non-participating NICUs within 24 hours after birth.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Collaborative antimicrobial stewardship groupCollaborative Antimicrobial Stewardship Program (ASP)Collaborative antimicrobial stewardship intervention will be implemented in NICUs of this group.
Primary Outcome Measures
NameTimeMethod
Total antibiotic days of therapy (DOT) per 1000 patient-daysup to 180 days

DOT is calculated as the sum of days of antibiotics used per patient.

Secondary Outcome Measures
NameTimeMethod
Total antibiotic days of therapy (DOT) per 1000 patient-days of third-generation cephalosporinup to 180 days

DOT is calculated as the sum of days of third-generation cephalosporin used per patient.

Total antibiotic days of therapy (DOT) per 1000 patient-days of fourth-generation cephalosporinup to 180 days

DOT is calculated as the sum of days of fourth-generation cephalosporin used per patient.

Total antibiotic days of therapy (DOT) per 1000 patient-days of piperacillin-tazobactamup to 180 days

DOT is calculated as the sum of days of piperacillin-tazobactam used per patient.

Total antibiotic days of therapy (DOT) per 1000 patient-days of carbapenemup to 180 days

DOT is calculated as the sum of days of carbapenem used per patient.

Total antibiotic days of therapy (DOT) per 1000 patient-days of vancomycinup to 180 days

DOT is calculated as the sum of days of vancomycin used per patient.

Total antibiotic days of therapy (DOT) per 1000 patient-days of linezolidup to 180 days

DOT is calculated as the sum of days of linezolid used per patient.

Incidence rate of infections caused by multi-resistant bacteriaup to 180 days

Multi-resistant bacteria include carbapenem-resistant Enterobacter, methicillin-resistant Staphylococcus aureus \[MRSA\], vancomycin-resistant Enterococcus \[VRE\], multi-resistant Acinetobacter, multi-resistant Pseudomonas aeruginosa.

Incidence rate of invasive fungal infectionsup to 180 days
Incidence of mortalityup to 180 days

Overall mortality and infection-related mortality

Incidences of major morbiditiesup to 180 days

Major morbidities include late-onset sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity and severe brain injury.

Length of hospital stayup to 180 days

Trial Locations

Locations (26)

The Affiliated Hospital of Qingdao University

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

Shaanxi Provincial People's Hospital

πŸ‡¨πŸ‡³

Xi'an, Shaanxi, China

Children' s Hospital of Fudan University

πŸ‡¨πŸ‡³

Shanghai, Shanghai, China

The First Affiliated Hospital of Xinjiang Medical University

πŸ‡¨πŸ‡³

Ürümqi, Xinjiang, China

First Affiliated Hospital of Kunming Medical University

πŸ‡¨πŸ‡³

Kunming, Yunnan, China

Children's Hospital of Shanghai

πŸ‡¨πŸ‡³

Shanghai, Shanghai, China

Fujian Maternity and Child Health Hospital

πŸ‡¨πŸ‡³

Fuzhou, Fujian, China

Quanzhou Women and Children's Hospital

πŸ‡¨πŸ‡³

Quanzhou, Fujian, China

Gansu Provincial Maternity and Child Care Hospital

πŸ‡¨πŸ‡³

Lanzhou, Gansu, China

Guangzhou Women and Children's Medical Center

πŸ‡¨πŸ‡³

Guangzhou, Guangdong, China

Women and Children's Hospital of Guangxi Zhuang Autonomous Region

πŸ‡¨πŸ‡³

Nanning, Guangxi, China

Henan Children's Hospital

πŸ‡¨πŸ‡³

Zhengzhou, Henan, China

The Third Affiliated Hospital of Zhengzhou University

πŸ‡¨πŸ‡³

Zhengzhou, Henan, China

Nanjing Maternity and Child Health Care Hospital

πŸ‡¨πŸ‡³

Nanjing, Jiangsu, China

Hunan Children's Hospital

πŸ‡¨πŸ‡³

Changsha, Hunan, China

Qingdao Women and Children's Hospital

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

People's Hospital of Xinjiang Uygur Autonomous Region

πŸ‡¨πŸ‡³

Ürümqi, Xinjiang, China

Tianjin Obstetrics & Gynecology Hospital

πŸ‡¨πŸ‡³

Tianjin, Tianjin, China

Northwest Women's and Children's Hospital

πŸ‡¨πŸ‡³

Xi'an, Shaanxi, China

Guizhou Women and Children's Hospital/Guiyang Children's Hospital

πŸ‡¨πŸ‡³

Guiyang, Guizhou, China

Shenzhen Maternity and Child Health Care Hospital

πŸ‡¨πŸ‡³

Shenzhen, Guangdong, China

Children's Hospital of Nanjing Medical University

πŸ‡¨πŸ‡³

Nanjing, Jiangsu, China

Suzhou Municipal Hospital affiliated to Nanjing Medical University

πŸ‡¨πŸ‡³

Suzhou, Jiangsu, China

Children's Hospital of Soochow University

πŸ‡¨πŸ‡³

Suzhou, Jiangsu, China

General Hospital of Ningxia Medical University

πŸ‡¨πŸ‡³

Xining, Ningxia, China

The First Bethune Hospital of Jilin University

πŸ‡¨πŸ‡³

Changchun, Jilin, China

Β© Copyright 2025. All Rights Reserved by MedPath